leap-011: first-line pembrolizumab plus lenvatinib for uc
Published 4 years ago • 147 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
2:41
leap-011: exploring first-line pembrolizumab lenvatinib for advanced urothelial carcinoma
-
2:21
lba41 - leap-005: phase ii study of lenvatinib plus pembrolizumab
-
0:34
pembrolizumab plus enfortumab vedotin for bladder cancer
-
6:38
lenvatinib plus pembrolizumab for advanced melanoma that progressed on a pd-1 or pd-l1 inhibitor...
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
1:09
keynote-045 – pembrolizumab as second-line treatment in urothelial carcinoma
-
1:14
bladder: enfortumab vedotin pembrolizumab & vesper trial
-
1:58
results for first-line pembrolizumab in advanced urothelial carcinoma
-
1:07
dr. balar on impact of durvalumab plus tremelimumab in bladder cancer
-
1:47
current and upcoming clinical trials in bladder cancer
-
4:21
durvalumab for treatment of advanced bladder cancer
-
3:25
enfortumab vedotin with pembrolizumab for bladder cancer
-
1:21
dr. o’donnell on pd-l1 testing in bladder cancer
-
1:07
dr. petrylak on the results of the ev-103 trial in bladder cancer
-
0:51
dr. balar on the approval of pembrolizumab for bladder cancer
-
2:09
enfortumab vedotin for bladder cancer
-
1:25
dr. balar on imvigor 210 results for metastatic urothelial carcinoma
-
2:41
firstline pembrolizumab for metastatic urothelial cancer
-
0:50
maintenance therapy for patients with advanced urothelial carcinoma